Beyond Air shares draw attention after revenue growth and reduced expenses support its LungFit PH commercial rollout.
Stock Earnings Results
June 26, 2026
Table of Contents
June 26, 2026
Beyond Air, Inc. (NASDAQ: XAIR) reported fiscal fourth-quarter and full-year 2026 results with higher revenue, lower full-year net loss, reduced operating expenses, and new revenue guidance tied to its LungFit PH commercial rollout.
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory conditions, with its LungFit PH system approved for certain neonatal hypoxic respiratory failure uses.
No analyst estimate data was provided in the supplied release.
Fiscal fourth-quarter revenue increased 66% to $1.9 million from $1.2 million a year earlier.
Gross profit improved to $94,000, compared with a gross loss of $32,000 in the prior-year quarter, mainly due to higher sales.
Research and development expenses fell 30% to $2.3 million. Selling, general, and administrative expenses increased 28% to $5.0 million, mainly due to one-time severance and related charges.
Net loss attributable to common stockholders was $10.3 million, or $0.77 per share, compared with a net loss of $8.0 million, or $1.79 per share, a year earlier.
For the full fiscal year, revenue increased 107% to $7.7 million from $3.7 million. Net loss improved to $33.2 million, or $4.01 per share, compared with a net loss of $46.6 million, or $13.77 per share, in fiscal 2025.
Beyond Air said revenue growth was driven by increased demand for LungFit PH in the U.S. and international markets.
The company also expanded its global distribution network to cover more than 45 countries and secured a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. GPO, its third major U.S. GPO relationship.
The main upcoming catalyst is the FDA review of Beyond Air’s PMA supplement for the second-generation LungFit PH system, submitted in June 2025.
If approved, the second-generation system is expected to offer a smaller footprint, lower weight, simplified operation, longer service intervals, and expanded flexibility. The company is also seeking labeling that would allow use during patient transport by air and ground.
Management said approval could expand the U.S. addressable market for the LungFit platform to approximately $400 million and the worldwide market to more than $1 billion.
Beyond Air is changing its fiscal year-end from March 31 to December 31.
The company guided for calendar 2026 revenue of $8 million, representing approximately 15% growth compared with calendar 2025.
For calendar 2027, Beyond Air expects revenue of $16 million to $18 million, representing more than 110% growth at the midpoint, assuming the commercial launch of the second-generation LungFit PH system.
As of March 31, 2026, Beyond Air had $17.3 million in cash, cash equivalents, restricted cash, and marketable securities. Long-term debt was $21.6 million, and the company had $18.2 million remaining available under its equity line of credit.
Beyond Air also said Nasdaq granted its request to continue listing, subject to regaining compliance with the minimum bid price rule by July 31, 2026. Following stockholder approval, the board approved a 1-for-20 reverse stock split expected to help regain compliance.
Beyond Air’s update showed progress, but the story remains centered on execution and regulatory timing.
Revenue more than doubled for the full fiscal year, expenses declined, and the net loss narrowed. Still, the company remains loss-making and needs the LungFit PH commercial ramp to accelerate.
The biggest swing factor is the second-generation LungFit PH system. If approved with expanded transport labeling, it could materially increase Beyond Air’s addressable market and support the company’s 2027 growth outlook.
Platforms like LevelFields track earnings beats, layoffs, dividend increases, leadership changes, dividend updates, and stock reactions together, helping investors identify when small-cap healthcare stocks are moving on regulatory catalysts or commercial traction.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE